News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Paolo Tarantino: Dato-DXd is the Latest ADC to be Approved for Treating HR+/HER2- MBC
Paolo Tarantino/X
Jun 5, 2025, 08:58

Paolo Tarantino: Dato-DXd is the Latest ADC to be Approved for Treating HR+/HER2- MBC

Paolo Tarantino, 2025 Yvonne ‘Top Voice’ Award Winner, Research Fellow at Dana-Farber Cancer Institute, shared a post on LinkedIn:

“Dato-DXd is the latest ADC to be approved for treating HR+/HER2- MBC, joining two other topo1 ADCs (T-DXd, SG).
How should we sequence these agents?
We conducted multiple rounds of polling to generate consensus within the Dana-Farber Cancer Institute Breast Oncology group.
The resulting consensus document is now published.”

Read More.

Dato-DXd

More posts featuring Paolo Tarantino on OncoDaily.

 

cancer Dana-Farber Cancer Institute Dato-DXd Datopotamab deruxtecan (Dato-DXd) OncoDaily Oncology Paolo Tarantino Paolo Tarantino: Dato-DXd is the Latest ADC to Be Approved for Treating HR+/HER2- MBC
Special Coverage
Drugs
Jun 5, 2025, 08:58
Paolo Tarantino: Dato-DXd is the Latest ADC to be Approved for Treating HR+/HER2- MBC
Blog
Jun 5, 2025, 08:47
Pashtoon Kasi: What is Evolving for ctDNA Liquid Biopsies?
Blog
Jun 5, 2025, 08:38
Zainab Shinkafi-Bagudu to Make History as First African UICC President in 2026 - CancerWorld
Blog
Jun 5, 2025, 08:31
Thor Halfdanarson: PRRT in NETs - Efficacy and Risk of Treatment-Related Myeloid Neoplasms
Blog
Jun 5, 2025, 08:09
Jemma Arakelyan: Honored to speak at ASCO 2025 on the hidden impacts of conflict on cancer care
Blog
Jun 5, 2025, 08:06
Garo Armen on Agenus's Recent Partnership with Zydus Group to Advance Immunotherapy in India
Insight
Jun 5, 2025, 07:54
Jonathan Spicer: Why is CM816 so important?
Blog
Jun 5, 2025, 07:40
Gevorg Tamamyan Reflects on the 2025 ASCO Annual Meeting and the Yvonne Awards
Blog
Jun 5, 2025, 06:15
Kleida Mati Has Been Awarded a Partial Scholarship to Pursue The Master’s in Molecular Oncology - European School of Oncology
Dialogues
Jun 5, 2025, 06:10
Levi Garraway: Transforming Oncology Through Precision, Resilience And Heart
Blog
Jun 5, 2025, 05:59
A Vibrant Few Days at The ASCO2025 Annual Meeting in Chicago - SPCC
Blog
Jun 5, 2025, 05:45
Alique Topalian: ASCO25 Conference Was a Great Success